Treatment of arthritis with TNF-alpha blockers - 4-Year follow-up;TNF-α-blokker-behandling af artrit - Fire års opfølgning

Ugeskrift for Laeger

Volumn 165, Issue 48, 2003, Pages 4649-4652

  Petri, Anne ^b   Dreyer, Lene ^b   Danneskiold Samsøe, Bente ^b   Terslev, Lene ^b   Bliddal, Henning ^a  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; FOLLOW UP; HUMAN; INFLAMMATION; PATHOGENESIS; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 1642472730     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Baillieres Best Pract Res Clin Rheumatol 1999;13(4):577-97.
2. Feldmann M, Bondeson J, Brennan FM, Foxwell BM, Maini RN. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF alpha and minimise hazards? Ann Rheum Dis 1999;58(suppl 1):127-31.
3. Illei GG, Lipsky PE. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr Opin Immunol 2000;12(6):712-8.
4. van den Berg WB. Uncoupling of Inflammatory and Destructive Mechanisms in Arthritis. Semin Arthritis Rheum 2001;30(suppl 12):7-12.
5. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
6. Mantovani A, Locati M, Vecchi A et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001;22:328-36.
7. Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999;26(suppl 57):22-8.
8. Luong BT, Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. Ann Pharmacother 2000;34:743-60.
9. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
10. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
11. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
12. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995;50(suppl 1):1-14.
13. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999;130:478-86.
14. Criscione LG, St Clair EW, Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
15. Furst DE, Keystone EC, Breedveld FC et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2001;60(suppl 3):iii2-iii5.
16. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
17. Mathias SD, Colwell HH, Miller DP et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128-39.
18. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602
19. Den Broeder AA, Joosten LA, Saxne T et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation, Ann Rheum Dis 2002;61:311-8.
20. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.